

26,041 Deaths 2,448,362 Injuries Following COVID Shots in European Union's Database as Slovenia Suspends J&J Shot after Death of 20-Year-Old Student

By Brian Shilhavy

Global Research, September 30, 2021

Health Impact News 29 September 2021

Region: <u>Europe</u>

Theme: Science and Medicine

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at <a>@crg_globalresearch.

The European Union database of suspected drug reaction reports is <u>EudraVigilance</u>, and they are now reporting 26,041 fatalities, and 2,448,362 injuries, following COVID-19 injections.

A *Health Impact News* subscriber from Europe reminded us that this database maintained at EudraVigilance is only for countries in Europe who are part of the European Union (EU), which comprises 27 countries.

The total number of countries in Europe is much higher, almost twice as many, numbering around 50. (There are some differences of opinion as to which countries are technically part of Europe.)

So as high as these numbers are, they do NOT reflect all of Europe. The actual number in Europe who are reported dead or injured following COVID-19 shots would be much higher than what we are reporting here.

The EudraVigilance database reports that through September 25, 2021 there are 26,041 deaths and 2,448,362 injuries reported following injections of four experimental COVID-19 shots:

- COVID-19 MRNA VACCINE MODERNA (CX-024414)
- COVID-19 MRNA VACCINE PFIZER-BIONTECH
- COVID-19 VACCINE ASTRAZENECA (CHADOX1 NCOV-19)
- COVID-19 VACCINE JANSSEN (AD26.COV2.S)

From the total of injuries recorded, almost half of them (1,176,130) are serious injuries.

"Seriousness provides information on the suspected undesirable effect; it can be classified as 'serious' if it corresponds to a medical occurrence that results in death, is life-threatening, requires inpatient hospitalisation, results in another medically important condition, or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, or is a congenital anomaly/birth defect."

A *Health Impact News* subscriber in Europe ran the reports for each of the four COVID-19 shots we are including here. It is a lot of work to tabulate each reaction with injuries and fatalities, since there is no place on the <u>EudraVigilance</u> system we have found that tabulates all the results.



Since we have started publishing this, others from Europe have also calculated the numbers and confirmed the totals.*

Here is the summary data through September 25, 2021.

Total reactions for the mRNA vaccine Tozinameran (code BNT162b2,Comirnaty) from BioNTech/ Pfizer – 12,362 deaths and 1,054,741 injuries to 25/09/2021

- 28,662 Blood and lymphatic system disorders incl. 172 deaths
- 29,569 Cardiac disorders incl. 1,834 deaths
- 277 Congenital, familial and genetic disorders incl. 23 deaths
- 14,027 Ear and labyrinth disorders incl. 9 deaths
- 822 Endocrine disorders incl. 5 deaths
- 16,330 Eye disorders incl. 30 deaths
- 92,590 Gastrointestinal disorders incl. 514 deaths
- 274,633 General disorders and administration site conditions incl. 3,517 deaths
- 1,186 Hepatobiliary disorders incl. 59 deaths

- 10,876 Immune system disorders incl. 65 deaths
- 36,113 Infections and infestations incl. 1,214 deaths
- 13,804 Injury, poisoning and procedural complications incl. 191 deaths
- 26,554 Investigations incl. 387 deaths
- 7,555 Metabolism and nutrition disorders incl. 225 deaths
- 138,223 Musculoskeletal and connective tissue disorders incl. 155 deaths
- 837 Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl. 78 deaths
- 185,082 Nervous system disorders incl. 1,341 deaths
- 1,347 Pregnancy, puerperium and perinatal conditions incl. 39 deaths
- 172 Product issues incl. 1 death
- 19,436 Psychiatric disorders incl. 159 deaths
- 3,605 Renal and urinary disorders incl. 205 deaths
- 24,848 Reproductive system and breast disorders incl. 4 deaths
- 46,177 Respiratory, thoracic and mediastinal disorders incl. 1,443 deaths
- 50,420 Skin and subcutaneous tissue disorders incl. 111 deaths
- **2,007** Social circumstances incl. 15 deaths
- 1,034 Surgical and medical procedures incl. 34 deaths
- 28,555 Vascular disorders incl. 532 deaths

Total reactions for the mRNA vaccine mRNA-1273 (CX-024414) from Moderna – 6,907 deaths and 306,490 injuries to 25/09/2021

- 6,051 Blood and lymphatic system disorders incl. 67 deaths
- 9,283 Cardiac disorders incl. 744 deaths
- 122 Congenital, familial and genetic disorders incl. 3 deaths
- 3,769 Ear and labyrinth disorders incl. 1 death
- 248 Endocrine disorders incl. 2 deaths
- 4,627 Eye disorders incl. 20 deaths
- 26,405 Gastrointestinal disorders incl. 269 deaths
- 82,564 General disorders and administration site conditions incl. 2,617 deaths
- 500 Hepatobiliary disorders incl. 29 deaths
- 2,659 Immune system disorders incl. 11 deaths
- 9,570 Infections and infestations incl. 487 deaths
- 6,759 Injury, poisoning and procedural complications incl. 127 deaths
- 5,811 Investigations incl. 128 deaths
- **2**,944 Metabolism and nutrition disorders incl. 158 deaths
- 38,397 Musculoskeletal and connective tissue disorders incl. 139 deaths
- 369 Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl. 42 deaths
- 53,562 Nervous system disorders incl. 706 deaths
- 583 Pregnancy, puerperium and perinatal conditions incl. 8 deaths
- 62 Product issues incl. 2 deaths
- 5,772 Psychiatric disorders incl. 118 deaths
- 1,772 Renal and urinary disorders incl. 114 deaths
- 4,576 Reproductive system and breast disorders incl. 5 deaths
- 13,315 Respiratory, thoracic and mediastinal disorders incl. 682 deaths
- 16,453 Skin and subcutaneous tissue disorders incl. 62 deaths
- 1,366 Social circumstances incl. 28 deaths
- 1,032 Surgical and medical procedures incl. 71 deaths

■ 7,919 Vascular disorders incl. 267 deaths

Total reactions for the vaccine AZD1222/VAXZEVRIA (CHADOX1 NCOV-19) from Oxford/ AstraZeneca - 5,468 deaths and 1,008,357 injuries to 25/09/2021

- 12,160 Blood and lymphatic system disorders incl. 226 deaths
- 17,334 Cardiac disorders incl. 623 deaths
- 163 Congenital familial and genetic disorders incl. 6 deaths
- 11,826 Ear and labyrinth disorders incl. 1 death
- 522 Endocrine disorders incl. 4 deaths
- 17,753 Eye disorders incl. 26 deaths
- 97,985 Gastrointestinal disorders incl. 280 deaths
- 265,482 General disorders and administration site conditions incl. 1,320 deaths
- 866 Hepatobiliary disorders incl. 53 deaths
- **4**,104 Immune system disorders incl. 25 deaths
- 26,800 Infections and infestations incl. 347 deaths
- 11,472 Injury poisoning and procedural complications incl. 153 deaths
- 22,152 Investigations incl. 129 deaths
- 11,805 Metabolism and nutrition disorders incl. 77 deaths
- 151,690 Musculoskeletal and connective tissue disorders incl. 76 deaths
- 536 Neoplasms benign malignant and unspecified (incl cysts and polyps) incl. 17 deaths
- 209,576 Nervous system disorders incl. 872 deaths
- 456 Pregnancy puerperium and perinatal conditions incl. 11 deaths
- 164 Product issues incl. 1 death
- 18,858 Psychiatric disorders incl. 50 deaths
- 3,752 Renal and urinary disorders incl. 49 deaths
- 13,707 Reproductive system and breast disorders incl. 2 deaths
- 35,537 Respiratory thoracic and mediastinal disorders incl. 654 deaths
- 46,297 Skin and subcutaneous tissue disorders incl. 40 deaths
- 1,328 Social circumstances incl. 7 deaths
- 1,199 Surgical and medical procedures incl. 24 deaths
- 24,833 Vascular disorders incl. 395 deaths

Total reactions for the COVID-19 vaccine JANSSEN (AD26.COV2.S) from <u>Johnson & Johnson</u> – 1,304 deaths and 78,774 injuries to 25/09/2021

- 737 Blood and lymphatic system disorders incl. 32 deaths
- 1,315 Cardiac disorders incl. 129 deaths
- 26 Congenital, familial and genetic disorders
- 687 Ear and labyrinth disorders incl. 1 death
- 47 Endocrine disorders incl. 1 death
- 1,067 Eye disorders incl. 6 deaths
- 7,102 Gastrointestinal disorders incl. 59 deaths
- 20.536 General disorders and administration site conditions incl. 333 deaths
- 98 Hepatobiliary disorders incl. 9 deaths
- 321 Immune system disorders incl. 7 deaths
- 1,943 Infections and infestations incl. 79 deaths
- 743 Injury, poisoning and procedural complications incl. 17 deaths
- 3,998 Investigations incl. 79 deaths

- 465 Metabolism and nutrition disorders incl. 29 deaths
- 12,263 Musculoskeletal and connective tissue disorders incl. 33 deaths
- Neoplasms benign, malignant and unspecified (incl cysts and polyps) incl. 2 deaths
- 16,253 Nervous system disorders incl. 148 deaths
- 26 Pregnancy, puerperium and perinatal conditions incl. 1 death
- 21 Product issues
- 1,059 Psychiatric disorders incl. 11 deaths
- 311 Renal and urinary disorders incl. 15 deaths
- 1,139 Reproductive system and breast disorders incl. 4 deaths
- 2,786 Respiratory, thoracic and mediastinal disorders incl. 148 deaths
- 2,426 Skin and subcutaneous tissue disorders incl. 5 deaths
- 235 Social circumstances incl. 4 deaths
- 572 Surgical and medical procedures incl. 43 deaths
- 2,561 Vascular disorders incl. 109 deaths

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

The original source of this article is <u>Health Impact News</u> Copyright © <u>Brian Shilhavy</u>, <u>Health Impact News</u>, 2021

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Brian Shilhavy

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca